Executive Summary
Publicis Groupe S.A. gains a stable $373.9M revenue stream via subsidiary Plowshare Group from CDC's National Tobacco Education Campaign, with $275.5M already outlayed and $123.9M in unexercised options through 2026-03-30. This Time & Materials award underscores reliable U.S. government demand in health advertising. Monitor remaining $98.4M obligated spend and post-2026 follow-ons for upside amid funding risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 29, 2026.
Investment Signals (1)
- $374M CDC Contract Bolsters Publicis Revenue (HIGH)▲
Multi-year Time & Materials delivery order provides predictable cash flow, with 74% ($275M) already disbursed toward total obligation.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Time & Materials structure exposes to government audits on hours/rates; only $275M of $374M obligated has been outlayed.
- Regulatory [MEDIUM RISK]▼
Extended term to 2026-03-30 vulnerable to HHS/CDC funding cuts or non-renewal.
Opportunities (2)
- ◆
$123.9M unexercised options could lift total value to $497.8M.
- ◆
Potential follow-on contracts post-2026 in CDC tobacco campaigns.
Sector Themes (1)
- ◆
Full & open competition award highlights CDC's commitment to large-scale tobacco education via agencies.
Watch List (2)
- 👁
{"entity"=>"Publicis Groupe S.A.", "reason"=>"Subsidiary contract drives ~$374M obligation with $98M remaining.", "trigger"=>"Q4 2025 earnings for outlay updates or option news"}
- 👁
{"entity"=>"CDC Tobacco Campaign Budget", "reason"=>"End-2026 expiration risks renewal gap.", "trigger"=>"FY2027 HHS appropriations bill"}
Get daily alerts with 1 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals